Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fostamatinib in ARDS
NCT06564207Phase 2Not yet recruiting
- Sponsor
- Inova Health System
- Start
- Nov 2026
- Primary completion
- May 2027
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing Standard of Care (SOC) + Placebo with Standard of Care (SOC) + Fostamatinib (2 arms). Primary endpoint: Cumulative Incidence of Serious Adverse Events at 30 days. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
fostamatinib
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT06564207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06564207.